1-20 of 52
Fei Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4430.
https://doi.org/10.1182/blood-2023-185543
Published: 2023
Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Keshu Zhou, Mingyuan Sun, Xu Wei, Shuhua Yi, Junyuan Qi, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fuling Zhou, Jianying Huang, Huilan Liu, Aizong Shen, Liangquan Geng, Ru Feng, Chongyuan Xu, Wenbin Qian, Fei Li, Lihong Liu, Caixia Li, Xielan Zhao, Jie Jin, Hongmei Jing, Dongmei Ji, Fangfang Lyu, Zi Chen, Lichuang Men, Hengbang Wang, Ke Zhang, Liang Xu, Zhang Zhang, Dajun Yang, Jianxiang Wang, Jianyong Li, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1900.
https://doi.org/10.1182/blood-2023-183071
Published: 2023
Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6145.
https://doi.org/10.1182/blood-2023-177820
Published: 2023
Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Suning Chen, Yanli Zhang, Na Xu, Hui Sun, Li Weiming, Yunfan Yang, Zunmin Zhu, Minghui Duan, Sixuan Qian, Yu Zhu, Jianmin Luo, Xiaodong Wang, Wei Yang, Weiying Gu, Fei Li, Bingcheng Liu, Yunxiao Xu, Zhenfang Liu, Chunling Wang, Yirong Jiang, Li Meng, Qin Wen, Yanli Xu, Xingli Zou, Wei Wang, Yan Xue, Hao Xu, Kehong Bi, Fuling Zhou, Liangming Ma, Rong Fu, Guifang Ouyang, Kaiyang Ding, Depei Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1797.
https://doi.org/10.1182/blood-2023-179073
Published: 2023
Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Wei Yang, Sujun Gao, Xiaojing Yan, Rong Guo, Lijie Han, Fei Li, Yafei Wang, Junmin Li, Chunkang Chang, Haiping Yang, Ronghua Hu, Hongyan Tong, Xingli Zhao, Qiubai Li, Jingdong Zhang, Xin Du, Sanfang Tu, Cheng Zhang, Congmeng Lin, Xin Du, Zhenling Li, Ligen Liu, Zhenyu Li, Zheng Dong, Yixuan Yang, Qiying Lu, Wenzhi Tian, Zhijian Xiao
Journal: Blood
Blood (2023) 142 (Supplement 1): 320.
https://doi.org/10.1182/blood-2023-174420
Published: 2023
Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Yuqin Song, Luis Malpica, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Kaiyang Ding, Yao Liu, Zengjun Li, Neha Mehta-Shah, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai, Liqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Zhenfan Yang, Won Seog Kim, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 305.
https://doi.org/10.1182/blood-2023-172962
Published: 2023
Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huanling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Shanshan Suo, Wenjuan Yu, Jie Jin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1814.
https://doi.org/10.1182/blood-2023-179043
Published: 2023
Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao
Journal: Blood
Blood (2023) 142 (Supplement 1): 6928.
https://doi.org/10.1182/blood-2023-181351
Published: 2023
Journal Articles

Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up

Jianqiu Wu, Fei Li, Zhi-Jun Wuxiao, Weiyan Tang, Yue Teng, Yanyan Liu, Han Chu, Zhiya Wu, Yiwen Shen, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng
Journal: Blood
Blood (2023) 142 (Supplement 1): 6265.
https://doi.org/10.1182/blood-2023-181831
Published: 2023
Journal Articles

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Junyuan Qi, Lin Song, Xudong Wei, Zhimin Zhai, Anyou Wang, Daozi Jiang, Yang Liang, Fei Li, Zhongxing Jiang, Xuejun Zhang, Qunyi Guo, Hongmei Jing, Yajing Xu, Xiangmin Tong, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2908.
https://doi.org/10.1182/blood-2023-183088
Published: 2023
Journal Articles

A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yuerong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Shen Qian, Fugen Li, Meng Li, Tongyu Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 304.
https://doi.org/10.1182/blood-2023-180372
Published: 2023
Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4428.
https://doi.org/10.1182/blood-2023-185363
Published: 2023
Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Hang Su, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1677.
https://doi.org/10.1182/blood-2023-178710
Published: 2023
Journal Articles

AK117 (anti-CD47 monoclonal antibody) in Combination with Azacitidine for Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): AK117-103 Phase 1b Results

Miao Miao, Qingliang Teng, Depei Wu, Zhongxing Jiang, Songfu Jiang, Fei Li, Yang Liang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Hongyan Tong
Journal: Blood
Blood (2023) 142 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2023-179099
Published: 2023
Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Yuqin Song, JUN MA, Yan Xie, Huilai Zhang, Zhigang Peng, Yuerong Shuang, Fei Li, Yufu Li, Haiyan Yang, Xiuhua Sun, Liqun Zou, Yunhong Huang, Weili Zhao, Wenrong Huang, Hui Zhou, Mingying Liu, Weiwei Wang, Jing Xu, Yajie Wang, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 4458.
https://doi.org/10.1182/blood-2023-181385
Published: 2023
Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Yi Xia, Shuchao Qin, Wei Wu, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Wei Xu, Jianyong Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4642.
https://doi.org/10.1182/blood-2023-188925
Published: 2023
Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4411.
https://doi.org/10.1182/blood-2023-186099
Published: 2023
Journal Articles

Efficacy and Safety of CD19-Specific CAR-T Cell Therapy Following Immunochemotherapy in Newly Diagnosed B-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis

Yulan Zhou, Yulong Jin, Dexiang Ji, Fancong Kong, Yu Peng, Min Yu, Shixuan Wang, Xiaoye Cheng, Fei Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4843.
https://doi.org/10.1182/blood-2023-189192
Published: 2023
Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Fangfang Lyu, Junning Cao, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6140.
https://doi.org/10.1182/blood-2023-180373
Published: 2023